Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Berk

Showing results (291-300 of 1,307) with videos related to

Pageof 131
Sort By:
Biological Psychiatry|February 15, 2025
The Drug Discovery Drought in Bipolar Disorder: Barriers and SolutionsJee Hyun Kim, Ken Walder, Bruna Panizzutti, et al.
BMC Medicine|February 12, 2013
The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarctionYiming Wang, Xingde Liu, Dongfeng Zhang, et al.
CNS Drugs|February 2, 2013
Potential mechanisms of action of lithium in bipolar disorder. Current understandingGin S Malhi, Michelle Tanious, Pritha Das, et al.
BMC Psychiatry|July 12, 2013
Altered cardiac autonomic nervous function in depressionYiming Wang, Xun Zhao, Adrienne O'Neil, et al.
Trials|September 11, 2019
N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trialLauren Arancini, Chiara C Bortolasci, Seetal Dodd, et al.
Pharmacological Reports : PR|February 21, 2014
Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogressionGeorge Anderson, Marta Kubera, Weronika Duda, et al.
International Journal of Psychiatry in Clinical Practice|June 18, 2014
The relationship between depression and cardiovascular diseaseStephen McConnell, Felice N Jacka, Lana J Williams, et al.
The International Journal of Neuropsychopharmacology|February 16, 2026
Conceptual and pragmatic clinical implications of dichotomizing psychotropics as targeting physiology - physiomodal and pathology - pathomodalMichael Berk, Stephen M Stahl, Lakshmi Yatham, et al.
Discover Mental Health|November 16, 2023
Navigating the multiple dimensions of the creativity-mental disorder link: a Convergence Mental Health perspectiveDavid G Angeler, Erin Smith, Michael Berk, et al.
Inflammopharmacology|January 25, 2012
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitorsMichael Maes, Zdenĕk Fišar, Miguel Medina, et al.
Pageof 131

Showing results (291-300 of 1,307) with videos related to

Sort By:
Pageof 131
Biological Psychiatry|February 15, 2025
The Drug Discovery Drought in Bipolar Disorder: Barriers and SolutionsJee Hyun Kim, Ken Walder, Bruna Panizzutti, et al.
BMC Medicine|February 12, 2013
The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarctionYiming Wang, Xingde Liu, Dongfeng Zhang, et al.
CNS Drugs|February 2, 2013
Potential mechanisms of action of lithium in bipolar disorder. Current understandingGin S Malhi, Michelle Tanious, Pritha Das, et al.
BMC Psychiatry|July 12, 2013
Altered cardiac autonomic nervous function in depressionYiming Wang, Xun Zhao, Adrienne O'Neil, et al.
Trials|September 11, 2019
N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trialLauren Arancini, Chiara C Bortolasci, Seetal Dodd, et al.
Pharmacological Reports : PR|February 21, 2014
Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogressionGeorge Anderson, Marta Kubera, Weronika Duda, et al.
International Journal of Psychiatry in Clinical Practice|June 18, 2014
The relationship between depression and cardiovascular diseaseStephen McConnell, Felice N Jacka, Lana J Williams, et al.
The International Journal of Neuropsychopharmacology|February 16, 2026
Conceptual and pragmatic clinical implications of dichotomizing psychotropics as targeting physiology - physiomodal and pathology - pathomodalMichael Berk, Stephen M Stahl, Lakshmi Yatham, et al.
Discover Mental Health|November 16, 2023
Navigating the multiple dimensions of the creativity-mental disorder link: a Convergence Mental Health perspectiveDavid G Angeler, Erin Smith, Michael Berk, et al.
Inflammopharmacology|January 25, 2012
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitorsMichael Maes, Zdenĕk Fišar, Miguel Medina, et al.
Pageof 131